Compare D R Horton Inc (DHI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs ResMed Inc. — how do they compare? D R Horton Inc trades at $134.81 (market cap $37.99B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: D R Horton Inc is the larger of the two by market cap, and D R Horton Inc pays the higher dividend (1.33%). Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and ResMed Inc. for 51 Days on average.
| DHI | RMD | |
|---|---|---|
Market Cap | $37.99B | $31.89B |
Volume | 2,974,460 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $277.88 |
52-Week Low | $132.53 | $182.82 |
Typical Hold Time | 46 Days | 51 Days |
Enterprise Value | $43.09B | $31.24B |
Dividend Yield | 1.33% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DHI trades at $134.88, up 1.2% on the day, with a bearish technical signal and neutral oscillators. The stock has beaten earnings estimates in recent quarters, with a P/E of 12.95 and net income margin of 9.15%. Recent news highlights pressure from rising mortgage rates, with the 30-year fixed rate potentially spiking to 9% according to Selma Hepp on CNBC (2026-09-28), impacting homebuilder sentiment.
The outlook is mixed: strong fundamentals and analyst consensus price target of $156.57 offer upside, but macroeconomic risks from interest rates and housing market weakness pose headwinds. Earnings growth remains a key catalyst, yet affordability concerns could dampen near-term performance.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
